Cannabidiol in Anorexia Nervosa: A Double-Blind Randomized Placebo Controlled Pilot Study
| Journal | The International journal of eating disorders |
| Study Type | Randomized Trial |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Anorexia nervosa (AN) is a severe psychiatric disorder marked by an intense fear of gaining weight and persistent body dissatisfaction, both during periods of underweight and after weight restoration. The endocannabinoid system may offer therapeutic benefits, particularly in reducing anxiety. This randomized controlled trial of cannabidiol (CBD) investigated safety, tolerability, pharmacokinetics, and symptomatic improvement in AN. In a double-blind design, women with AN or Atypical AN were randomized to receive CBD (n = 16) or placebo (n = 16) over 21 days. The dose was up-titrated weekly from 1.25 mg/kg twice daily to a maximum of 6.25 mg/kg twice daily, while assessing CBD and metabolite levels, liver function, and severity of eating disorder, depression, and anxiety symptoms. Age at baseline was similar between the CBD and placebo group (22.9 ± 2.8 years vs. 22.5 ± 3.5 years), as was body mass index (BMI, kg/m This study suggests that CBD is well tolerated in individuals with AN. F
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
